OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
28
Results
Show all
Save search
Copy query
Show results for
Unknown
(28)
Publication Date
Release Date
2023
(7)
2025
(5)
2024
(5)
2022
(4)
2021
(4)
2016
(2)
2020
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425
|
biostudies-literature
Cite
Overweight duration in older adults and cancer risk: a study of cohorts in Europe and the United States.
Not available
S-EPMC5920679
|
biostudies-literature
Cite
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903
|
biostudies-literature
Cite
Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial.
Not available
S-EPMC11862976
|
biostudies-literature
Cite
Cost-effectiveness of procalcitonin-guided antibiotic duration for hospitalized patients with sepsis.
Not available
S-EPMC12661845
|
biostudies-literature
Cite
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7616743
|
biostudies-literature
Cite
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867
|
biostudies-literature
Cite
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031
|
biostudies-literature
Cite
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591
|
biostudies-literature
Cite
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets